Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow STRO by emailGet an email when STRO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about STRO, unsubscribe in one click. Privacy
📣 What STRO Says Is Next
in 2026 · “The program remains on track for IND submission in 2026 and represents a key component of Sutro’s strategy to expand its pipeline of novel-format dual-payload ADCs.”
Company press release, Aug 12, 2026 · SEC filing
in 2026 · “The program continues to advance toward clinical development, with an IND submission anticipated in 2026.”
Company press release, May 14, 2026 · SEC filing
this year · “In parallel, we are advancing STRO-006, our ITGB6 ADC, and accelerating STRO-227, our wholly owned dual-payload program targeting PTK7, toward IND submission this year.”
Company press release, Mar 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full STRO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for STRO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.